FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia - Report - MDSpire
Advertisement
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia
Deseyne delivers smooth, continuous focus across near, intermediate, and distance vision, which is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner.
Clinical Report: FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia
Overview
The FDA has approved Deseyne, the first daily disposable soft contact lens utilizing extended depth of focus (EDOF) technology for presbyopia. This lens offers continuous focus across near, intermediate, and distance vision, marking a significant advancement in non-surgical vision correction options.
Background
Presbyopia affects a significant portion of the aging population, leading to difficulties in near vision. Traditional solutions include reading glasses and multifocal lenses, but these may not meet all patients' needs. The introduction of EDOF contact lenses represents a novel approach to managing presbyopia, potentially improving patient satisfaction and adherence to vision correction.
Data Highlights
The FDA clearance was based on a multicenter, randomized, double-masked, active-controlled trial involving 78 participants, demonstrating the safety and efficacy of Deseyne compared to a single-vision control lens.
Key Findings
Deseyne utilizes patented EDOF optical design technology for enhanced vision.
The lens provides smooth, continuous focus across all distances.
Manufactured from vifilcon C hydrogel, it includes components for hydration and comfort.
Deseyne is indicated for daily wear in presbyopes with ≤1.00 D of astigmatism.
This is the first soft contact lens in the U.S. to explicitly name EDOF as its mechanism of action.
Clinical Implications
Clinicians should consider Deseyne as a viable option for presbyopic patients seeking non-surgical vision correction. The lens's design may enhance patient comfort and satisfaction, potentially leading to better adherence to prescribed vision correction.
Conclusion
The approval of Deseyne marks a significant advancement in the management of presbyopia, offering a new, effective option for patients. Ongoing clinical evaluations will further elucidate its long-term benefits in practice.
Study findings highlight communication barriers in ophthalmology and outline a structured framework designed to support understanding, expectation-setting, and adherence.
